Skip to content
2000
image of ELOVL4 is a Prognostic Biomarker with Implications for Immune Modulation and Therapeutic Response in Gastric Cancer

Abstract

Background

Gastric cancer (GC) remains a major health burden with poor prognosis, highlighting the need for reliable prognostic biomarkers and therapeutic targets. ELOVL4 (Elongation of Very Long Chain Fatty Acids Protein 4) is an enzyme involved in lipid metabolism, which has been implicated in various cancers, but its role in GC remains largely unexplored.

Methods

We evaluated the prognostic value of ELOVL4 expression in GC based on samples from The Cancer Genome Atlas (TCGA) database. Subsequently, we investigated the associations between ELOVL4 expression and tumor immune microenvironment features, including tumor microenvironment (TME) scores, immune cell infiltration, and immune checkpoint gene expression. Moreover, we assessed the correlation between ELOVL4 expression and tumor mutational burden (TMB) as well as drug sensitivity profiles. Functional and pathway enrichment analyses were performed to gain mechanistic insights.

Results and Discussion

High ELOVL4 expression was significantly associated with adverse clinical outcomes. A nomogram incorporating ELOVL4 expression was developed for individualized prognosis evaluation. Patients with high ELOVL4 expression exhibited an activated TME, with distinct immune cell infiltration patterns and correlations with immune checkpoint gene expression. Additionally, ELOVL4 expression was negatively correlated with TMB. Differential drug sensitivity profiles were identified between the high and low ELOVL4 expression groups. Enrichment analyses revealed the involvement of ELOVL4 in various biological processes and signaling pathways.

Conclusion

Our findings establish ELOVL4 as a biomarker for poor prognosis and therapeutic target in GC, with implications for prognosis evaluation, immune microenvironment modulation, and chemotherapeutic response.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240356824250116103049
2025-10-01
2025-12-13

  • From This Site

    /content/journals/cmm/10.2174/0115665240356824250116103049
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Wong M.C.S. Huang J. Chan P.S.F. Global incidence and mortality of gastric cancer, 1980-2018. JAMA Netw. Open 2021 4 7 e2118457 10.1001/jamanetworkopen.2021.18457 34309666
    [Google Scholar]
  2. Luo G. Zhang Y. Guo P. Wang L. Huang Y. Li K. Global patterns and trends in stomach cancer incidence: Age, period and birth cohort analysis. Int. J. Cancer 2017 141 7 1333 1344 10.1002/ijc.30835 28614909
    [Google Scholar]
  3. Yan X. Lei L. Li H. Stomach cancer burden in China: Epidemiology and prevention. Chin. J. Cancer Res. 2023 35 2 81 91 10.21147/j.issn.1000‑9604.2023.02.01 37180831
    [Google Scholar]
  4. Rawla P. Barsouk A. Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz. Gastroenterol. 2019 14 1 26 38 10.5114/pg.2018.80001 30944675
    [Google Scholar]
  5. Zhao L. Liu Y. Zhang S. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Cell Death Dis. 2022 13 4 378 10.1038/s41419‑022‑04821‑w 35444235
    [Google Scholar]
  6. Fu Y Zou T Shen X Lipid metabolism in cancer progression and therapeutic strategies MedComm (2020) 2020 2 1 27 59 10.1002/mco2.27 34766135
    [Google Scholar]
  7. Yeboah G.K. Lobanova E.S. Brush R.S. Agbaga M.P. Very long chain fatty acid-containing lipids: A decade of novel insights from the study of ELOVL4. J. Lipid Res. 2021 62 100030 10.1016/j.jlr.2021.100030 33556440
    [Google Scholar]
  8. Castell A.L. Vivoli A. Tippetts T.S. Very-long-chain unsaturated sphingolipids mediate oleate-induced rat β-cell proliferation. Diabetes 2022 71 6 1218 1232 10.2337/db21‑0640 35287172
    [Google Scholar]
  9. Bogie J.F.J. Haidar M. Kooij G. Hendriks J.J.A. Fatty acid metabolism in the progression and resolution of CNS disorders. Adv. Drug Deliv. Rev. 2020 159 198 213 10.1016/j.addr.2020.01.004 31987838
    [Google Scholar]
  10. Rugolo F. Bazan N.G. Calandria J. The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome. Oncogene 2021 40 38 5741 5751 10.1038/s41388‑021‑01959‑3 34333551
    [Google Scholar]
  11. Wang X. Yu H. Gao R. Liu M. Xie W. A comprehensive review of the family of very-long-chain fatty acid elongases: structure, function, and implications in physiology and pathology. Eur. J. Med. Res. 2023 28 1 532 10.1186/s40001‑023‑01523‑7 37981715
    [Google Scholar]
  12. Agostini M. Melino G. Habeb B. Calandria J.M. Bazan N.G. Targeting lipid metabolism in cancer. Neuroblastoma. Cancer Metastasis Rev 2022 41 2 255 260 10.1007/s10555‑022‑10040‑8 35687185
    [Google Scholar]
  13. Yoon S.J. Park J. Shin Y. Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model. BMC Cancer 2020 20 1 314 10.1186/s12885‑020‑06814‑4 32293340
    [Google Scholar]
  14. Shi Y. Wang Y. Dong H. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: Novel perspective to mRNA vaccines and personalized immunotherapy. Apoptosis 2023 28 9-10 1423 1435 10.1007/s10495‑023‑01868‑8 37369808
    [Google Scholar]
  15. Yoshihara K. Shahmoradgoli M. Martínez E. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013 4 1 2612 10.1038/ncomms3612 24113773
    [Google Scholar]
  16. Chen B. Khodadoust M.S. Liu C.L. Newman A.M. Alizadeh A.A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 2018 1711 243 259 10.1007/978‑1‑4939‑7493‑1_12 29344893
    [Google Scholar]
  17. Maeser D. Gruener R.F. Huang R.S. oncoPredict: An R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief. Bioinform. 2021 22 6 bbab260 10.1093/bib/bbab260 34260682
    [Google Scholar]
  18. Ritchie M.E. Phipson B. Wu D. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015 43 7 e47 10.1093/nar/gkv007 25605792
    [Google Scholar]
  19. Yu G. Wang L.G. Han Y. He Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012 16 5 284 287 10.1089/omi.2011.0118 22455463
    [Google Scholar]
  20. Wang Y. Yao J. Zhang Z. Wei L. Wang S. Generation of novel lipid metabolism-based signatures to predict prognosis and immunotherapy response for colorectal adenocarcinoma. Sci. Rep. 2024 14 1 17158 10.1038/s41598‑024‑67549‑x 39060344
    [Google Scholar]
  21. Kady N.M. Liu X. Lydic T.A. ELOVL4-mediated production of very long-chain ceramides stabilizes tight junctions and prevents diabetes-induced retinal vascular permeability. Diabetes 2018 67 4 769 781 10.2337/db17‑1034 29362226
    [Google Scholar]
  22. Gong Y. Liu X. Sahu A. Reddy A.V. Wang H. Exploration of hub genes, lipid metabolism, and the immune microenvironment in stomach carcinoma and cholangiocarcinoma. Ann. Transl. Med. 2022 10 15 834 10.21037/atm‑22‑3530 36034995
    [Google Scholar]
  23. Yu W. Lei Q. Yang L. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J. Hematol. Oncol. 2021 14 1 187 10.1186/s13045‑021‑01200‑4 34742349
    [Google Scholar]
  24. Bian G. Cao J. Li W. Identification and validation of a cancer-testis antigen-related signature to predict the prognosis in stomach adenocarcinoma. J. Cancer 2024 15 11 3596 3611 10.7150/jca.91842 38817874
    [Google Scholar]
  25. Vassiliou E. Farias-Pereira R. Impact of lipid metabolism on macrophage polarization: Implications for inflammation and tumor immunity. Int. J. Mol. Sci. 2023 24 15 12032 10.3390/ijms241512032 37569407
    [Google Scholar]
  26. Tu B. Gao Y. Sun F. Shi M. Huang Y. Lipid metabolism regulation based on nanotechnology for enhancement of tumor immunity. Front. Pharmacol. 2022 13 840440 10.3389/fphar.2022.840440 35392570
    [Google Scholar]
  27. Papalexi E. Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat. Rev. Immunol. 2018 18 1 35 45 10.1038/nri.2017.76 28787399
    [Google Scholar]
  28. Kobayashi Y. Lim S.O. Yamaguchi H. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Semin. Cancer Biol. 2020 65 51 64 10.1016/j.semcancer.2019.11.011 31874279
    [Google Scholar]
  29. Choucair K. Morand S. Stanbery L. Edelman G. Dworkin L. Nemunaitis J. TMB: A promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 2020 27 12 841 853 10.1038/s41417‑020‑0174‑y 32341410
    [Google Scholar]
  30. Wang Y. Li Z. He J. Zhao Y. Quercetin regulates lipid metabolism and fat accumulation by regulating inflammatory responses and glycometabolism pathways: A review. Nutrients 2024 16 8 1102 10.3390/nu16081102 38674793
    [Google Scholar]
  31. Deák F. Anderson R.E. Fessler J.L. Sherry D.M. Novel cellular functions of very long chain-fatty acids: Insight from ELOVL4 mutations. Front. Cell. Neurosci. 2019 13 428 10.3389/fncel.2019.00428 31616255
    [Google Scholar]
  32. Wang D. Ye Q. Gu H. Chen Z. The role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies. Front. Oncol. 2022 12 984560 10.3389/fonc.2022.984560 36172157
    [Google Scholar]
  33. Xia Z. Zhao N. Liu M. GPD1 inhibits the carcinogenesis of breast cancer through increasing PI3K/AKT-mediated lipid metabolism signaling pathway. Heliyon 2023 9 7 e18128 10.1016/j.heliyon.2023.e18128 37483742
    [Google Scholar]
  34. Garcia C. Andersen C.J. Blesso C.N. The role of lipids in the regulation of immune responses. Nutrients 2023 15 18 3899 10.3390/nu15183899 37764683
    [Google Scholar]
/content/journals/cmm/10.2174/0115665240356824250116103049
Loading
ELOVL4 is a Prognostic Biomarker with Implications for Immune Modulation and Therapeutic Response in Gastric Cancer
Bentham Science Publishers ; https://doi.org/10.2174/0115665240356824250116103049
/content/journals/cmm/10.2174/0115665240356824250116103049
/content/journals/cmm/10.2174/0115665240356824250116103049
Loading

Data & Media loading...

Supplements

Supplementary data are available as a PDF file.

file format download Download

  • Article Type:     Research Article
Keywords: gastric cancer ; ELOVL4 ; immune ; prognosis ; drug sensitivity

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test